Related Experiment Video
Updated: Jun 5, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.4K
Behavioral medicine in the GLP-1 era
1Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, United States.
Summary
Glucagon-like peptide-1 (GLP-1) agonists offer significant weight loss benefits but may medicalize weight and increase stigma. Behavioral medicine should focus on health markers, not just BMI, for inclusive care.
Area of Science:
- Behavioral Medicine
- Health Psychology
- Medical Ethics
Background:
- Glucagon-like peptide-1 (GLP-1) agonist medications are increasingly recognized for substantial weight loss effects.
- These medications present complex considerations for behavioral medicine and health psychology professionals.
- Potential benefits include improved health outcomes beyond weight loss and reduced weight management stigma.
Purpose of the Study:
- To critically examine the multifaceted implications of GLP-1 agonist medications within behavioral medicine and health psychology.
- To explore both the advantages and potential risks associated with these powerful weight-loss drugs.
- To advocate for a nuanced approach to their integration into clinical practice and research.
Main Methods:
- This is a commentary, not an empirical study. The authors synthesize existing knowledge and perspectives.
- Discussion involves analyzing the positive and negative aspects of GLP-1 agonists from clinical, social, and ethical viewpoints.
- Consideration of social identity theory and weight-inclusive care models informs the analysis.
Main Results:
- GLP-1 agonists show promise for health improvements independent of weight loss.
- Potential risks include the medicalization of weight, increased weight stigma, and the perception of GLP-1s as an "easy way out."
- From a social identity perspective, GLP-1s could be seen as targeting higher-weight individuals.
Conclusions:
- Clinical care should adopt a patient-centered, weight-inclusive approach, tailoring treatment to individual health and social contexts.
- Research in behavioral medicine should prioritize interventions targeting health markers and behaviors over solely focusing on BMI reduction.
- This shift will enhance health outcomes irrespective of a patient's weight or medication status.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:06Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
01:15Diabetes: Management and Pharmacotherapy
235
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
235
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159